Proteasomal inhibition reduces parkin mRNA in PC12 and SH-SY5Y cells

Gasser, 2005, Genetics of Parkinson's disease, Curr Opin Neurol, 18, 363, 10.1097/01.wco.0000170951.08924.3d Tan, 2007, Pathogenic mutations in Parkinson disease, Hum Mutat, 28, 641, 10.1002/humu.20507 Shimura, 2000, Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase, Nat Genet, 25, 302, 10.1038/77060 McNaught, 2003, Altered proteasomal function in sporadic Parkinson's disease, Exp Neurol, 179, 38, 10.1006/exnr.2002.8050 Haywood, 2006, Mutant alpha-synuclein-induced degeneration is reduced by parkin in a fly model of Parkinson's disease, Genome, 49, 505, 10.1139/G06-011 Lo Bianco, 2004, Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease, Proc Natl Acad Sci USA, 101, 17,510, 10.1073/pnas.0405313101 Yang, 2005, Neuroprotection of Parkin against apoptosis is independent of inclusion body formation, Neuroreport, 16, 1117, 10.1097/00001756-200507130-00017 Yang, 2006, Induction of parkin expression in the presence of oxidative stress, Eur J Neurosci, 24, 1366, 10.1111/j.1460-9568.2006.04998.x Jiang, 2004, Parkin protects human dopaminergic neuroblastoma cells against dopamine-induced apoptosis, Hum Mol Genet, 13, 1745, 10.1093/hmg/ddh180 Cha, 2005, Parkin negatively regulates JNK pathway in the dopaminergic neurons of Drosophila, Proc Natl Acad Sci USA, 102, 10,345, 10.1073/pnas.0500346102 Henn, 2007, Parkin mediates neuroprotection through activation of IkappaB kinase/nuclear factor-kappaB signaling, J Neurosci, 27, 1868, 10.1523/JNEUROSCI.5537-06.2007 Chung, 2001, Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease, Nat Med, 7, 1144, 10.1038/nm1001-1144 Ito, 2003, Dorfin localizes to Lewy bodies and ubiquitylates synphilin-1, J Biol Chem, 278, 29,106, 10.1074/jbc.M302763200 Liani, 2004, Ubiquitylation of synphilin-1 and alpha-synuclein by SIAH and its presence in cellular inclusions and Lewy bodies imply a role in Parkinson's disease, Proc Natl Acad Sci U S A, 101, 5500, 10.1073/pnas.0401081101 Engelender, 1999, Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions, Nat Genet, 22, 110, 10.1038/8820 Dächsel, 2005, Parkin interacts with the proteasome subunit alpha4, FEBS Lett, 579, 3913, 10.1016/j.febslet.2005.06.003 West, 2003, Identification of a novel gene linked to parkin via a bi-directional promoter, J Mol Biol, 326, 11, 10.1016/S0022-2836(02)01376-1 Junn, 2002, Parkin accumulation in aggresomes due to proteasome impairment, J Biol Chem, 277, 47,870, 10.1074/jbc.M203159200 Imai, 2000, Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity, J Biol Chem, 275, 35,661, 10.1074/jbc.C000447200 West, 2003, Parkin is not regulated by the unfolded protein response in human neuroblastoma cells, Neurosci Lett, 341, 139, 10.1016/S0304-3940(03)00188-5 Wang, 2007, Cell type-specific upregulation of Parkin in response to ER stress, Antioxid Redox Signal, 9, 533, 10.1089/ars.2006.1522 Yamamoto, 2005, Parkin phosphorylation and modulation of its E3 ubiquitin ligase activity, J Biol Chem, 280, 3390, 10.1074/jbc.M407724200 McNaught, 2004, Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease, Ann Neurol, 56, 149, 10.1002/ana.20186 Schapira, 2006, Proteasomal inhibition causes loss of nigral tyrosine hydroxylase neurons, Ann Neurol, 60, 253, 10.1002/ana.20934 Kordower, 2006, Failure of proteasome inhibitor administration to provide a model of Parkinson's disease in rats and monkeys, Ann Neurol, 60, 264, 10.1002/ana.20935 Manning-Bog, 2006, Lack of nigrostriatal pathology in a rat model of proteasome inhibition, Ann Neurol, 60, 256, 10.1002/ana.20938 Hampe, 2006, Biochemical analysis of Parkinson's disease-causing variants of Parkin, an E3 ubiquitin-protein ligase with monoubiquitylation capacity, Hum Mol Genet, 15, 2059, 10.1093/hmg/ddl131 Wang, 2005, Stress-induced alterations in parkin solubility promote parkin aggregation and compromise parkin's protective function, Hum Mol Genet, 14, 3885, 10.1093/hmg/ddi413 Tan, 2005, Impaired transcriptional upregulation of Parkin promoter variant under oxidative stress and proteasomal inhibition: clinical association, Hum Genet, 118, 484, 10.1007/s00439-005-0038-4 Biasini, 2004, Proteasome inhibition and aggregation in Parkinson's disease: a comparative study in untransfected and transfected cells, J Neurochem, 88, 545, 10.1046/j.1471-4159.2003.02152.x